Spruce Biosciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $148.2M
- Price
- $51.58
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.78%
- Volume
- 62.3K
About
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
Quick stats
Shares outstanding2.9M
Computed float2.5M
Float / shares86.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001683553
Websitehttps://www.sprucebio.com
AI Summary
AI-generated1/30
majorbullishearnings
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Spruce Biosciences reported a Q2 net loss of $16.2 million, or $(6.68) per share, while strengthening its balance sheet with $96.3 million in cash, sufficient to fund operations into the second half of 2027.
The company confirmed that the Biologics License Application (BLA) for its lead asset TA-ERT is anticipated in Q4 2026, alongside the initiation of the TrAnsform confirmatory study and an Expanded Access Program.
Strategic corporate updates included a $5.5 million investment from patient advocacy foundations and the appointment of Dr. Adrian Quartel as CMO and Dr. Jessica Cohen Pfeffer as VP of Clinical Development.
Red flags
- Discontinuation of the tildacerfont program reduces pipeline diversification
- Pre-revenue status with ongoing quarterly losses